^
    Back
    Association details:
    Biomarker:FLT3-ITD F692L + NPM1 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) +
    MI-503 (Menin-MLL inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2019
    Title:

    Combined Targeting of the Menin-MLL1 Chromatin Complex and FLT3 As a Novel Therapeutic Concept Against NPM1 Mutant or MLL-Rearranged AML with Mutated FLT3

    Published date:
    11/06/2019
    Excerpt:
    As the murine Npm1mut Flt3ITD AML cells harbor the Flt3ITD F692L gatekeeper mutation that conveys drug resistance to most FLT3 inhibitors, we used Ponatinib as a combination partner for MI503 in these cells and found similar synergistic suppression of proliferation and colony formation.
    DOI:
    10.1182/blood-2019-122847